Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ: ARWR · IEX Real-Time Price · USD
28.92
0.00 (0.00%)
At close: Nov 28, 2023, 12:00 AM
29.00
+0.08 (0.29%)
Pre-market: Nov 29, 2023, 9:06 AM EST
0.00%
Market Cap 3.13B
Revenue (ttm) 256.21M
Net Income (ttm) -181.11M
Shares Out 107.19M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Ex-Dividend Date n/a
Volume 16,072
Open 29.48
Previous Close 28.92
Day's Range 27.92 - 29.10
52-Week Range 22.87 - 42.48
Beta 0.88
Analysts Buy
Price Target 55.60 (+92.25%)
Earnings Date Nov 29, 2023

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 1993
Employees 397
Stock Exchange NASDAQ
Ticker Symbol ARWR
Full Company Profile

Financial Performance

In 2022, ARWR's revenue was $243.23 million, an increase of 75.89% compared to the previous year's $138.29 million. Losses were -$176.06 million, 25.0% more than in 2021.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $55.6, which is an increase of 92.25% from the latest price.

Price Target
$55.6
(92.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO...

1 day ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th An...

7 days ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to disc...

13 days ago - Business Wire

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3...

16 days ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Heal...

23 days ago - Business Wire

Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of ...

27 days ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast ...

2 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 26, 2023, t...

2 months ago - Business Wire

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, in...

2 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi's 18th Annual Bio...

3 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a...

4 months ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss...

4 months ago - Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO...

4 months ago - Business Wire

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SO...

5 months ago - Business Wire

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-99...

5 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Global Healt...

6 months ago - Business Wire

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m. ET to discuss progress towards the...

6 months ago - Business Wire

Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company's inves...

6 months ago - Business Wire

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating A...

7 months ago - Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2023 RBC Capi...

7 months ago - Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting...

7 months ago - Business Wire

Arrowhead Pharmaceuticals' Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, the company's investiga...

7 months ago - Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss it...

8 months ago - Business Wire

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET ...

8 months ago - Business Wire

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda's (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinica...

8 months ago - Business Wire